You are here: Industry Insights > Market News > Three-fold increase in remdesivir production in India: Mansukh Mandaviya

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

Three-fold increase in remdesivir production in India: Mansukh Mandaviya

expresspharmaMay 07, 2021

Tag: Remdesivir , Mansukh Mandaviya , India

Favorites

The production of remdesivir is being increased at a rapid pace in the country. In just a few days, India has achieved three times the production capacity of the medicine, and will soon be able to meet the growing demand, informed Mansukh Mandaviya, Minister of State for Chemical and Fertilizers via Twitter yesterday.

He also wrote, “In view of the increase in demand, the number of plants producing remdesivir has also gone up from 20 on 12th April, 2021 to 57 on 4th May, 2021.”

Further, the production has gone up from 37 lakh on 12th April, 2021 to 1.05 crore on 4th May, 2021, according to a statement by Ministry of Chemicals and Fertilizers.

Previous:RBI announces on-tap liquidity window of Rs 50,000 cr for healthcare infra, services firms

Next:MoHF&W issues guidelines for COVID-19 vaccine import by private sector

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Three-fold increase in remdesivir production in India: Mansukh Mandaviya | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Three-fold increase in remdesivir production in India: Mansukh Mandaviya

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Three-fold increase in remdesivir production in India: Mansukh Mandaviya

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>